Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
257 Leser
Artikel bewerten:
(1)

Genhealth AI: GenHealth.ai Launches AI-Powered Order Automation Solution for Home and Durable Medical Equipment Providers

Revolutionizing DME Operations: Seamless Automation from Intake to Billing

BOSTON, MASSACHUSETTS / ACCESS Newswire / June 4, 2025 / GenHealth.ai today announced the launch of its AI-powered automation solution specially designed for Durable Medical Equipment (DME) and Home Medical Equipment (HME) providers, helping relieve the burden of complex workflows such as medical order intake, eligibility verification, and prior authorizations. This launch marks a major expansion of GenHealth.ai's mission to bring intelligent, scalable automation to healthcare operations-boosting accuracy, reducing delays, and accelerating access to care.

Developed in close partnership with early DME customers, GenHealth.ai's platform streamlines the medical order lifecycle using new advancements in AI and Large Language Models (LMMs)-combined with deep integrations into existing EMR and billing systems-specifically for DME and HME providers.

Key capabilities include:

  • Automated Patient Intake: Consolidates all incoming orders-fax, email, EHR, and portals-into a single inbox. Processes even handwritten forms and fills in data to billing systems and electronic medical records.

  • Real-Time Coverage & Eligibility Checks: Verifies insurance coverage through clearinghouses or direct payer integrations, extracting key plan-level details like deductible status, coverage limits, and co-pays.

  • Medical Necessity & Prior Auth Submission: Compares clinical documentation-such as physician notes-against payer policy requirements, identifying gaps in real time, ensuring every order is audit-ready before it hits the billing queue.

  • Seamless Billing Integration: Pushes claim-ready orders directly into systems like Brightree and NikoHealth, eliminating rekeying and toggling between platforms.

  • Deep Insight into Payment Analytics: Compare reimbursement rates against historical benchmarks and peer performance metrics?using GenHealth's Large Medical Model (LMM).

Early Results: Less Manual Work. Higher Accuracy

Across early implementations, GenHealth.ai has delivered:

  • 4x increase in orders processed per employee

  • 50% reduction in manual review time

  • 95%+ alignment with human utilization management (UM) decisions

"With AI, customers are able to bring on our AI agent to help their existing teams process more cases and increase revenue while reducing administrative costs." said Ethan Siegel, CPO. Ricky Sahu, CEO, added "DME providers deserve tools that reduce friction across every step of the order process-and they shouldn't have to rip out their systems to make it work. Our AI integrates into existing customer apps without disrupting how their teams work today."

Expanding the Vision for Smarter Healthcare Operations

In addition to the DME solution, GenHealth.ai has developed a prior authorization automation solution for providers, designed to accelerate access to high-cost therapies such as GLP-1s and chemotherapies. By combining AI, patient charts, and payer-specific coverage logic, the platform helps providers achieve faster patient-centered approvals-resulting in higher approval rates.

GenHealth.ai will be showcasing these capabilities live at the VGM Heartland Conference in Waterloo, IA, on June 10-11, 2025 and at ENDO 2025 in San Francisco, CA, on July 12-14, 2025.

About GenHealth.ai

GenHealth.ai is a healthcare automation company building AI-powered infrastructure for modern care delivery. The company's platform uses a proprietary Large Medical Model (LMM) to understand real-world clinical data, payer requirements, and operational workflows. GenHealth.ai helps providers, DME suppliers, and care teams reduce administrative burden, improve accuracy, and accelerate patient access to care-all through intelligent, end-to-end automation.

To learn more, contact hello@genhealth.ai or visit www.genhealth.ai

Contact Information

Mike Maseda
Head of Operations
marketing@genhealth.ai

.

SOURCE: Genhealth AI



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/genhealth.ai-launches-ai-powered-order-automation-solution-for-home-a-1034636

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.